The WHO CNS5 classification underscores the centrality of molecular markers in glioma diagnosis and prognosis, including IDH mutation, 1p/19q co-deletion, and CDKN2A/B homozygous deletion [2]. This evidence concerns the gene IDH1 and central nervous system cancer.